ASSOCIATION FOR ACCESSIBLE MEDICINES for ASSOCIATION FOR ACCESSIBLE MEDICINES
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
General Trade Issues. Trans-Pacific Partnership (TPP). Transatlantic Trade and Investment Partnership (TTIP). Biologic Exclusivity. North American Free Trade Agreement.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN BILLINGS | — |
| CHRISTOPHER BOWLIN | — |
| MICHAEL BRZICA | — |
| CHRISTIAN OMAR CRUZ | — |
| JEFFREY FRANCER | — |
| DAVID R. GAUGH | — |
| ERIK C KOMENDANT | — |
| KRISTIN MURPHY New | Executive Assistant, U.S. Representative Rick Larsen |
| RACHEL L. SHER New | Senior Policy Analyst, Food and Drug Administration; Senior FDA Counsel, Energy and Commerce Committee; FDA Counsel, U.S. Representative Henry Waxman |
Taxation/Internal Revenue Code TAX
Taxation Issues Related to Opioid Pharmaceuticals. User Fee Programs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN BILLINGS | — |
| CHRISTOPHER BOWLIN | — |
| MICHAEL BRZICA | — |
| CRAIG BURTON | — |
| CHRISTIAN OMAR CRUZ | — |
| THOMAS JAMES GARRIGAN | — |
| DAVID R. GAUGH | — |
| ERIK C KOMENDANT | — |
| KRISTIN MURPHY New | Executive Assistant, U.S. Representative Rick Larsen |
Copyright/Patent/Trademark CPT
Inter Partes Review (IPR) process. Patent Settlements. S.1390: STRONGER Patents Act of 2017.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN BILLINGS | — |
| CHRISTOPHER BOWLIN | — |
| MICHAEL BRZICA | — |
| CHRISTIAN OMAR CRUZ | — |
| JEFFREY FRANCER | — |
| THOMAS JAMES GARRIGAN | — |
| DAVID R. GAUGH | — |
| ERIK C KOMENDANT | — |
| KRISTIN MURPHY New | Executive Assistant, U.S. Representative Rick Larsen |
| RACHEL L. SHER New | Senior Policy Analyst, Food and Drug Administration; Senior FDA Counsel, Energy and Commerce Committee; FDA Counsel, U.S. Representative Henry Waxman |
| CHRISTINE SIMMON | — |
Medicare/Medicaid MMM
Medicare Part D Program and Generic Drugs. Medicare reimbursement for biosimilars. Medicaid Rebate Penalty. Medicare Part D Low Income Subsidy (LIS) Program.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN BILLINGS | — |
| CHRISTOPHER BOWLIN | — |
| MICHAEL BRZICA | — |
| CRAIG BURTON | — |
| CHRISTIAN OMAR CRUZ | — |
| CHESTER DAVIS | — |
| THOMAS JAMES GARRIGAN | — |
| ERIK C KOMENDANT | — |
| KRISTIN MURPHY New | Executive Assistant, U.S. Representative Rick Larsen |
| CHRISTINE SIMMON | — |
Budget/Appropriations BUD
FDA Funding. S.2956: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2017. H.R.5054: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2017. S.Con.Res.3: A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026. H.R.3354: Department of the Interior, Environment, and Related Agencies Appropriations Act, 2018.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN BILLINGS | — |
| CHRISTOPHER BOWLIN | — |
| MICHAEL BRZICA | — |
| CHRISTIAN OMAR CRUZ | — |
| JEFFREY FRANCER | — |
| DAVID R. GAUGH | — |
| ERIK C KOMENDANT | — |
| KRISTIN MURPHY New | Executive Assistant, U.S. Representative Rick Larsen |
Pharmacy PHA
Implementation of Food and Drug Administration Safety and Innovation Act (FDASIA) and Generic Drug User Fee Amendments (GDUFA). Biosimilar User Fee Act (BsUFA). Labeling of Generic Drugs. Biosimilars Naming. Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products. Prescription Drug Costs. H.R.2051: FAST Generics Act of 2017. S.124: Preserve Access to Affordable Generics Act. H.R.1245/S.469: Affordable and Safe Prescription Drug Importation Act. H.R.1314: Bipartisan Budget Act of 2015. Risk Evaluation and Mitigation Strategies (REMS). Biologic Exclusivity. Biologics Price Competition and Innovation Act (BPCIA). H.R.2562/S.1115: Making Pharmaceutical Markets More Competitive Act. S.771: Improving Access To Affordable Prescription Drugs Act. Pharmaceutical Exclusivity. H.R.2212/S.974: CREATES Act of 2017. H.R.6043/S.3335: Fair Accountability and Innovative Research Drug Pricing Act of 2016. S.297: Increasing Competition in Pharmaceuticals Act. H.R.749: Lower Drug Costs through Competition Act. H.R.2430/S.934: FDA Reauthorization Act of 2017. H.R.1223/S.1509: Orphan Products Extension Now Accelerating Cures and Treatments Act of 2017.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN BILLINGS | — |
| CHRISTOPHER BOWLIN | — |
| MICHAEL BRZICA | — |
| CRAIG BURTON | — |
| CHRISTIAN OMAR CRUZ | — |
| CHESTER DAVIS | — |
| JEFFREY FRANCER | — |
| THOMAS JAMES GARRIGAN | — |
| DAVID R. GAUGH | — |
| ERIK C KOMENDANT | — |
| KRISTIN MURPHY New | Executive Assistant, U.S. Representative Rick Larsen |
| RACHEL L. SHER New | Senior Policy Analyst, Food and Drug Administration; Senior FDA Counsel, Energy and Commerce Committee; FDA Counsel, U.S. Representative Henry Waxman |
| CHRISTINE SIMMON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.